Furthermore, in female C57BL/6 mice with induced metabolic syndrome and emphysema, treatment with the GLP-1 receptor agonist has been shown to reduce the area of emphysema, as well as to increase the number of CD31+ endothelial cells, probably through reduced inflammation and positive effects on lipid and glucose metabolism. This evidence concerns the gene PECAM1 and pulmonary emphysema.